Phase 2a Study of Dapivirine Ring in Adolescent Females
Status:
Completed
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
To assess the safety of dapivirine (25 mg) administered via a silicone vaginal ring in
HIV-uninfected adolescent females, when inserted once every 4 weeks during 12 weeks of study
product use
Phase:
Phase 2
Details
Lead Sponsor:
International Partnership for Microbicides, Inc.
Collaborators:
Microbicide Trials Network National Institutes of Health (NIH)